Qualigen Therapeutics, Inc.
QLGN
$5.23
-$0.36-6.44%
NASDAQ
| 06/30/2025 | 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | |
|---|---|---|---|---|---|
| Net Income | 14.23% | 54.36% | 65.10% | 63.80% | 40.51% |
| Total Depreciation and Amortization | -- | -- | -- | 50.00% | 50.00% |
| Total Amortization of Deferred Charges | -62.74% | -71.85% | -73.02% | -58.52% | -0.22% |
| Total Other Non-Cash Items | -70.73% | -91.83% | -6.64% | -135.78% | -61.02% |
| Change in Net Operating Assets | -175.10% | -158.28% | -195.27% | -82.91% | -69.52% |
| Cash from Operations | 3.47% | 15.62% | 38.59% | -41.62% | 36.26% |
| Capital Expenditure | -- | -- | -- | -- | -- |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | -184.62% | -158.05% | -153.54% | -127.16% | 1,009.21% |
| Cash from Investing | -178.46% | -150.12% | -145.24% | -117.79% | 1,058.45% |
| Total Debt Issued | 1,056.84% | 478.95% | -- | -14.77% | -83.64% |
| Total Debt Repaid | -378.36% | -354.36% | -354.36% | -379.55% | -- |
| Issuance of Common Stock | -- | -- | -- | -- | -- |
| Repurchase of Common Stock | -- | -- | -- | -- | -- |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -- | -- | -- | -- | -- |
| Cash from Financing | 899.60% | 12,476.93% | 1,737.76% | 96.25% | -63.02% |
| Foreign Exchange rate Adjustments | -- | -- | -- | -- | -204.42% |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | 117.34% | 98.53% | 111.64% | -722.70% | 85.38% |